SG10201911442XA - Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid - Google Patents

Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Info

Publication number
SG10201911442XA
SG10201911442XA SG10201911442XA SG10201911442XA SG10201911442XA SG 10201911442X A SG10201911442X A SG 10201911442XA SG 10201911442X A SG10201911442X A SG 10201911442XA SG 10201911442X A SG10201911442X A SG 10201911442XA SG 10201911442X A SG10201911442X A SG 10201911442XA
Authority
SG
Singapore
Prior art keywords
thioxothiazolidin
ylidene
furan
oxo
benzyl
Prior art date
Application number
SG10201911442XA
Other languages
English (en)
Inventor
Antonio J Barbosa
Original Assignee
Gb006 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gb006 Inc filed Critical Gb006 Inc
Publication of SG10201911442XA publication Critical patent/SG10201911442XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201911442XA 2015-06-12 2016-06-10 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid SG10201911442XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175066P 2015-06-12 2015-06-12
US201662275655P 2016-01-06 2016-01-06

Publications (1)

Publication Number Publication Date
SG10201911442XA true SG10201911442XA (en) 2020-02-27

Family

ID=57504544

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201911442XA SG10201911442XA (en) 2015-06-12 2016-06-10 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Country Status (12)

Country Link
US (3) US10723726B2 (enrdf_load_stackoverflow)
EP (1) EP3307722B1 (enrdf_load_stackoverflow)
JP (1) JP2018521121A (enrdf_load_stackoverflow)
KR (1) KR102663856B1 (enrdf_load_stackoverflow)
CN (1) CN107848991B (enrdf_load_stackoverflow)
AU (2) AU2016275125A1 (enrdf_load_stackoverflow)
BR (2) BR122023025347A2 (enrdf_load_stackoverflow)
CA (2) CA3221219A1 (enrdf_load_stackoverflow)
ES (1) ES2896674T3 (enrdf_load_stackoverflow)
IL (1) IL256237B (enrdf_load_stackoverflow)
SG (1) SG10201911442XA (enrdf_load_stackoverflow)
WO (1) WO2016201356A1 (enrdf_load_stackoverflow)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023025347A2 (pt) 2015-06-12 2024-01-16 Gb006, Inc. Sal de meglumina ou trometamina de um composto, formas cristalinas e formulações farmacêuticas dos mesmos e seus usos
US20200123146A1 (en) * 2016-12-29 2020-04-23 Gb006, Inc. Heterocyclic integrin agonists
KR20190136037A (ko) * 2017-03-30 2019-12-09 메르크 파텐트 게엠베하 (s)-[2-클로로-4-플루오로-5-(7-모르폴린-4-일퀴나졸린-4-일)페닐]-(6-메톡시-피리다진-3-일)메탄올의 고체 형태
WO2020108154A1 (zh) 2018-11-28 2020-06-04 罗欣药业(上海)有限公司 一种雌激素受体下调剂的盐型、晶型及其制备方法
WO2020236667A1 (en) * 2019-05-17 2020-11-26 Gb006, Inc. Methods of treating cancer
WO2021061665A1 (en) * 2019-09-23 2021-04-01 Gb006, Inc. Integrin agonist prodrugs
WO2021096988A1 (en) 2019-11-12 2021-05-20 Gb006, Inc. Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
WO2024081449A1 (en) * 2022-10-14 2024-04-18 Rush University Medical Center Cd11b agonists for treatment of autoimmune disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
EP1654380A4 (en) 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
ITMI20042475A1 (it) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Uso di derivati tiazolidinonici come agenti terapeutici
WO2008005651A2 (en) * 2006-06-08 2008-01-10 Decode Chemistry, Inc. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
WO2008082537A2 (en) 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
CN103159695B (zh) * 2011-12-08 2015-08-12 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
AU2013248972A1 (en) 2012-04-20 2014-11-13 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
BR122023025347A2 (pt) 2015-06-12 2024-01-16 Gb006, Inc. Sal de meglumina ou trometamina de um composto, formas cristalinas e formulações farmacêuticas dos mesmos e seus usos

Also Published As

Publication number Publication date
WO2016201356A1 (en) 2016-12-15
US20230227443A1 (en) 2023-07-20
CN107848991B (zh) 2022-01-14
CN107848991A (zh) 2018-03-27
US20200317657A1 (en) 2020-10-08
KR20180016443A (ko) 2018-02-14
CA3221219A1 (en) 2016-12-15
US10723726B2 (en) 2020-07-28
KR102663856B1 (ko) 2024-05-07
AU2016275125A1 (en) 2018-01-25
CA2988584C (en) 2024-01-23
US12227497B2 (en) 2025-02-18
EP3307722A1 (en) 2018-04-18
US11111239B2 (en) 2021-09-07
EP3307722B1 (en) 2021-08-04
BR112017026406A2 (pt) 2019-04-02
AU2020270457B2 (en) 2022-10-20
US20180354938A1 (en) 2018-12-13
IL256237A (en) 2018-02-28
NZ738836A (en) 2024-03-22
CA2988584A1 (en) 2016-12-15
ES2896674T3 (es) 2022-02-25
AU2020270457A1 (en) 2020-12-10
EP3307722A4 (en) 2018-12-05
BR122023025347A2 (pt) 2024-01-16
JP2018521121A (ja) 2018-08-02
IL256237B (en) 2021-12-01

Similar Documents

Publication Publication Date Title
IL256237B (en) Solid forms of (z) - 4 - (5 - ((3 - benzyl - 4 - oxo - 2 - thioxothiazolidine - 5 - ylidin) methyl) furan - 2 - yl) benzoic acid
IL259698B (en) Crystalline 2- (3-ethanesulfonylfluoridine-2-yl)-5- (trifluoromethanesulfonyl)benzoxazole
HUE047477T2 (hu) Palbociclib szilárd dózisformái
SI3371190T1 (sl) Heterociklične spojine kot inhibitorji PI3K gama
KR102254062B9 (ko) 삼나트륨 발사르탄:사쿠비트릴의 고체 형태
IL257026A (en) Solid state forms of eluxadoline
ITUB20155853A1 (it) Composizione di legante inorganico per colata
DK3351633T3 (da) Antisense-nukleinsyre
SG11201707384YA (en) Crystal of 3,5-disubstituted benzene alkynyl compound
EP3310439A4 (en) PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS
PL3107392T3 (pl) Kompozycje grzybobójcze alkoksyamidów kwasu pirazolokarboksylowego
SG11201507336WA (en) Solid forms of 5-(halomethyl) furfural and methods for preparing thereof
HRP20181570T1 (hr) Režim doziranja spoja fgf-18
PL3107391T3 (pl) Grzybobójcze kompozycje alkoksyamidów kwasów pirazolokarboksylowych
IL254502A0 (en) Solid forms of menaquinols
DK3373931T3 (da) Heterocykliske forbindelser til behandling af sygdom
HUE064755T2 (hu) Alfa-halo-akrilsav-származékok átmenetifém-katalizált protodekarboxilezõdése
DK3389638T3 (da) Farmaceutisk sammensætning omfattende pimobendan
EP3319595A4 (en) ENCAPSULATED ACTIVE SUBSTANCES FOR CONTROLLED ENTERAL ACTIVE COMPOSITION
DK3280920T3 (da) Reversibel forbindelse af maskinkomponenter
EP3250540B8 (en) Preparation of compounds from levulinic acid
DK3283066T3 (da) 4-Phenylsmørsyrederivater
IL253055B (en) A method for the preparation of certain tetrazoles converted in positions 1 and 5
ES1142181Y (es) Juego de ladrillos caravista
FR3033739B3 (fr) Tenseur pour baches de bennes de chargement